Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $75.00 | Outperform | Oppenheimer |
| 5/27/2025 | $72.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
| 12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 11/23/2021 | $55.00 | Outperform | Oppenheimer |
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CTJefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limit
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours a
GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte